Immuneonco Biopharmaceuticals (shanghai) Inc Class H · HKEX:1541
Immuneonco Biopharmaceuticals (shanghai) Inc Class H — H1 2026 Earnings Presentation
30 slides from Immuneonco Biopharmaceuticals (shanghai) Inc Class H's earnings presentation, 2026
Slide 1: 2026 Interim Results Presentation
2026 Interim Results Presentation
Slide 2: Disclaimer
Disclaimer By reading this presentation and ancillary materials (together, the “Materials”), you agree to be bound by the following limitations: The Materials are strictly confidential, are not for public dissemination and are for the exclusive use of persons who are authorised to receive the Materi
Slide 3: Business Outlook
OY, Business Outlook
Slide 4: 2026 Business Highlights and Milestones
2026 Business Highlights and Milestones Timdarpacept •1L CMML Ph III on track: all subjects enrolled in Jun 2026; data cutoff expected by year-end, then interim analysis （IMM01） • Jan 2026: atherosclerosis received Ph II IND approval; spinal cord injury animal data were encouraging. •R/R FL Ph III +
Slide 5: Pipeline
IND/IND Phase III/ Commercial Program (1) Target (Modality) Indication(s) Discovery Preclinical Phase Ia/I Phase Ib/II Enabling Pivotal Rights IMM01 (timdarpacept) CD47 IMM01 + Azacitidine (SIRPα-Fc fusion protein) 1L CMML China (NMPA) Global Atherosclerosis China (NMPA) Global IMM01(timdarpacept) C
Slide 6: Integrated proprietary R&D platform
Integrated proprietary R&D platform Efficient Screening and Optimize Molecule Structure Cost-effective In-house Next-generation Innovative Druggability Analysis Design Manufacturing Oncology Therapies Target Selection and AI-enabled Drug High-throughput CMC and IND- Molecule Design Preclinical Studi
Slide 7: rHuPH20 SC Platform: Strategic Driver for Industrial Upgrade
rHuPH20 SC Platform: Strategic Driver for Industrial Upgrade Mechanism of rHuPH20 Scarce competitive barrier rHuPH20 locally degrades hyaluronic acid (HA), removing the • Few have in-house originator rHuPH20 production SC barrier to enable rapid, large-volume SC dosing. HA recovers • From mAb-Trap d
Slide 8: Three Strategic Product Matrices Drive Future Growth
Three Strategic Product Matrices Drive Future Growth Proprietary R&D platform and multi-layered innovative pipeline •Differentiated design balances efficacy and safety • Ph II data selected for ASCO/ESMO/ASH oral presentations •IMM01 may become the first approved CD47 drug Hematologic/Solid tumors •
Slide 9: Core Pipeline Progress
OY, Core Pipeline Progress
Slide 10: IMM01: Potential First Approved CD47 Drug Globally
IMM01: Potential First Approved CD47 Drug Globally IMM01 is China's first SIRPα-Fc fusion protein in clinical Blocks CD47/SIRPα "don't eat me" + FcγR "eat me" development. Engineered to avoid human RBC binding, it eliminates IMM01 Full activation of macrophages SIRPα Blocking “Don’t eat me” low-dose
Slide 11: IMM01 in CMML: First Potential New Drug in ~20 Years
IMM01 in CMML: First Potential New Drug in ~20 Years 1L CMML (N=22) 1L HR-MDS (N=51) R/R cHL (N=33) IMM01+AZA vs Chinese retrospective study IMM01+AZA vs AZA monotherapy meta-analysis IMM01+PD-1 vs competitor combos 100 100 100 80 72.7 80 80 69.7 64.7 60 60 50.0 60 % 35.3 % % 37.5 40 40 40 33.3 29.0
Slide 12: IMM01 in Atherosclerosis: New Non-Oncology CD47 Indication
IMM01 in Atherosclerosis: New Non-Oncology CD47 Indication Reduced plaque hemorrhage (HE) and increased collagen (Masson's) in mice A B 8 80 ### Intraplaque hemorrhage **** **** (% of lesion area) 60 (% of lesion area) 6 Collagen area 4 40 ** **** 2 **** **** 20 0 0 kg e g kg cl k kg e g kg g/ g/ g/
Slide 13: IMM0306: First-in-Class CD47×CD20 Bispecific MCE
IMM0306: First-in-Class CD47×CD20 Bispecific MCE First CD47×CD20 bispecific drug to enter clinical trials Overview Mechanism of Action IMM0306 molecular structure Full macrophage activation IgG4 CD47 mAb SIRPα-D1 SIRPα "Don't eat me" blocked "Eat me" off Enhanced ADCP and ADCC activity CD47 Anti-CD2
Slide 14: IMM0306+LEN: Leading R/R FL Efficacy; Phase III FPI
IMM0306+LEN: Leading R/R FL Efficacy; Phase III FPI Cross-trial ORR & CR Comparison (R/R FL) ORR (%) CR (%) 100 88.6 100 80.3 83.5 79.0 78.7 80 80 65.9 60 60 52.0 38.0 34.7 40 40 20 15.5 20 0 0 IMM0306 Obinutuzumab Obinutuzumab Rituximab Tafasitamab IMM0306 Obinutuzumab Obinutuzumab Rituximab Tafasi
Slide 15: IMM0306 + Len: Favorable Safety in R/R FL, 1L FL Ph II Enrollment Completed
IMM0306 + Len: Favorable Safety in R/R FL, 1L FL Ph II Enrollment Completed Non-hematologic AE rates vs marketed CD20×CD3 bispecifics (%) IMM0306+len IMM0306+len Mosun Mosun Epcor Epcor Adverse events (All Grade) (Grade ≥3) (All Grade) (Grade ≥3) (All Grade) (Grade ≥3) Immune disorders CRS 1.3 0 44
Slide 16: IMM0306: Strong SLE Efficacy and Safety; Phase II FPI
IMM0306: Strong SLE Efficacy and Safety; Phase II FPI CD47×CD20 bispecific fusion protein | Ph Ib open-label dose escalation | Data cutoff: Mar 5, 2026 SRI-4（Week 24） • SRI-4 up to 80%, sustained through Week 52 Deep B-cell depletion + recovery Rapid and complete B-cell depletion 100 80.0 80 71.4 72
Slide 17: Innovative Ph II Design: IV IMM0306 & SC IMM0306S in SLE
Innovative Ph II Design: IV IMM0306 & SC IMM0306S in SLE Blinded phase (W1-24) Open-label phase (W25-52) IV IMC-002 cohort Treatment arm 1: IMC-002 1.2 mg/kg IV QW (W1-W4) Treatment arm 1: IMC-002 1.2 mg/kg IV QW (W25-W28) 1:1:1 randomization Treatment arm 2: IMC-002 1.6 mg/kg IV QW (W1-W4) Treatmen
Slide 18: IMM0306 Autoimmune Disease Pipeline: Substantial Market Potential
IMM0306 Autoimmune Disease Pipeline: Substantial Market Potential 40 million+ patients 8 major indications 6 INDs approved 3 clinical trials initiated Potential autoimmune patients in China Core autoimmune diseases INDs approved in China SLE IV & SC IgG4-RD NMOSD LN PMN pSS Phase Ib Phase II Phase I
Slide 19: IMM2510: First ADCC-Enhanced PD-L1×VEGF Bispecific
IMM2510: First ADCC-Enhanced PD-L1×VEGF Bispecific Target Introduction and Molecular Structure IMM2510 Molecular Structure IMM2510 binding to various VEGFs 5 VEGF-A VEGF VEGFR1-D2 VEGF-B 4 VEGF-C VEGF receptor trap binds more VEGF 3 VEGF-D OD450 ligands, incl. VEGF-A, for broader anti- PIGF angiogen
Slide 20: IMM2510: Durable Efficacy and Safety in IO-Resistant SQ-NSCLC
IMM2510: Durable Efficacy and Safety in IO-Resistant SQ-NSCLC SC formulation: one dose cohort enrolled Efficacy data (N=22) Safety (N=32) ORR DCR • Zero deaths No TEAE led to death 27.3% 81.8% (88.2%)* • Low discontinuation rate Only 3.1% discontinued due to TRAEs 6/22 PR 18/22 • No Grade ≥3 immune-
Slide 21: IMM2510+IMM27M in Advanced Solid Tumors; 1L HCC Ph II FPI
IMM2510+IMM27M in Advanced Solid Tumors; 1L HCC Ph II FPI IMM2510 (VEGF×PD-L1) blocks angiogenesis + relieves PD-L1 immunosuppression; IMM27M (enhanced CTLA-4 mAb) further activates T cells Phase Ib/II clinical trial Preliminary data in ESCC Efficacy in 6 ESCC patients Expansion & New Indications Co
Slide 22: IMC-003 (ActRIIA-Fc) Ph Ib/II in PAH Initiated
IMC-003 (ActRIIA-Fc) Ph Ib/II in PAH Initiated PAH market expected to approach RMB 100B by 2032 IMC-003 binds more strongly than sotatercept Binding of ACVR2 Fc Fusion Protein to Activin-A 4 Sotatercept 3 ACVR2A(Wt)-Fc ACVR2A(Mut1)-Fc OD450 2 ACVR2A(Mut2)-Fc ACVR2A(Mut3)-Fc 1 hIgG1 0 0.001 0.01 0.1
Slide 23: IMC-004 (RANKL×ActRIIA): Osteoporosis Exploration
IMC-004 (RANKL×ActRIIA): Osteoporosis Exploration •RANKL binds its receptor RANK to stimulate osteoclastogenesis, thereby inducing osteoporosis; •Activin A drives osteoclasts and blocks osteoblast mineralization. ActRIIA-Fc blocks Activin A: fewer osteoclasts, more osteoblasts, higher bone density (
Slide 24: IMC-015 (IMM9101): Muscle Gain & Fat Loss
IMC-015 (IMM9101): Muscle Gain & Fat Loss Global obesity market: US$140.3B in 2023, projected US$351.8B by 2033; next-gen therapies should reduce fat while preserving muscle. • Source from: https://sixpeaksbio.com/platform/
Slide 25: IMC-015 (IMM9101): Muscle Gain & Fat Loss
IMC-015 (IMM9101): Muscle Gain & Fat Loss Design: leverages muscle-specific GDF-8 and ActRII's fat-reducing, muscle-preserving effects; vs bimagrumab, lower ActRIIA/B-related toxicity for better efficacy and fewer AEs. ActRII biology in adipose tissue Activin signaling via ActRII promotes lipid stor
Slide 26: IMC-011 (IMM91): Pro/Latent GDF-8 mAb for Muscle Gain
IMC-011 (IMM91): Pro/Latent GDF-8 mAb for Muscle Gain IMC-011 shows strong binding/blocking SRK-015 (apitegromab) validated the target Binding to latent GDF-8 •SRK-015: a fully human antibody that binds •Ph II: lean mass preserved during weight loss 2.5 2.0 IMC-011 pro/latent myostatin Emugrobart/mI
Slide 27: Future Outlook
OY, Future Outlook
Slide 28: Mid- to Long-Term Development Strategy
Mid- to Long-Term Development Strategy Accelerate core clinical programs Expand non-oncology areas •Advance IMM01 Ph III in CMML •Advance autoimmune indications for IMM0306 • Advance IMM0306 Ph III (R/R FL) and Ph II (SLE) • Advance IMC-003 in PAH •Advance IMM2510 Ph III (SQ-NSCLC) prep, • Explore I
Slide 29: Q&A
OY, Q&A
Slide 30: Thank you!
Thank you！
ImmuneOnco Biopharmaceuticals (Shanghai) — H1 2026 Earnings Presentation on 6ix